Pharmacogenomics in drug development: Societal and technical aspects

Pharmacogenomics Journal

Volumn 4, Issue 4, 2004, Pages 226-232

  Bartfai, T ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; APOLIPOPROTEIN E; BIOLOGICAL MARKER; CYTOCHROME P450 2D6; DNA; NEU DIFFERENTIATION FACTOR; NEW DRUG; TRASTUZUMAB;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALZHEIMER DISEASE; ARTICLE; BREAST CANCER; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG INDUSTRY; DRUG LEGISLATION; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; ECONOMIC ASPECT; FOOD AND DRUG ADMINISTRATION; GENETIC LINKAGE; GENETIC SUSCEPTIBILITY; GENETIC TOXICOLOGY; GENOTYPE; HAPLOTYPE; HEALTH CARE INDUSTRY; HEALTH CARE ORGANIZATION; HEREDITY; HLA TYPING; HUMAN; MEDICAL DECISION MAKING; MEDICAL ETHICS; MEDICAL GENETICS; MEDICAL PRACTICE; MORALITY; PHARMACOGENOMICS; POLITICS; PRIORITY JOURNAL; RISK ASSESSMENT; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SOCIAL ASPECT;

BIOMEDICAL AND BEHAVIORAL RESEARCH; GENETICS AND REPRODUCTION;

DRUG INDUSTRY; GENOTYPE; HUMANS; PHARMACOGENETICS; SOCIAL BEHAVIOR;

EID: 4344665180     PISSN: 1470269X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500249     Document Type: Article

References (30)

1. Motulsky. Drug reactions, enzymes and biochemical genetics. JAMA (1957); 165: 835-837.
2. Vogel F. Moderne probleme der humangenetik. Ergeb Inn Med Kinderheilkd 1959; 12: 52-125.
3. Haldane. The Biochemistry of Genetics. George Allen &Unwin Ltd: London 1954.
4. Lesko LJ, Salerno RA, Spear BB, Anderson DC, Anderson T, Brazell C et al. Pharmacogenetics pharmacogenomics in drug development regulatory decision making: report of the first FDA-PWG-PhRMA-DruSafe Workshop. J Clin Pharmacol 2003; 43: 342-358.
5. Hauser ER, Mooser V, Crossman DC, Haines JL, Jones CH, Winkelmann BR et al. Design of the Genetics of Early Onset Cardiovascular Disease (GENECARD) study. Am Heart J 2003; 145: 602-613.
6. Roses AD. Pharmacogenetics. Hum Mol Genet 2001; 10: 2261-2267.
7. Emilien G, Ponchon M, Caldas C, Isacson O, Maloteaux JM. Impact of genomics on drug discovery clinical medicine. QJM 2000; 93: 391-423.
8. Freund CL, Wilfond BS. Emerging ethical issues in pharmacogenomics: from research to clinical practice. Am J Pharmacog 2002; 2: 273-281.
9. Gulcher JR, Stefansson K. Ethics of population genomics research [comment]. Nature 1999; 400: 307-308.
10. Licinio J. Pharmacogenomics ethnic minorities. Pharmacog J 2001; 1: 85.
11. Moldrup C. Ethical, social and legal implications of pharmacogenomics: a critical review. Commun Genet 2002; 4: 204-214.
12. Oestreicher P. 4th Annual Pharmacogenomics and Medicine Lectures. Pharmacogenomics 2001; 2: 291-296.
13. Roses AD. Genome-based pharmacogenetics and the pharmaceutical industry. Nat Rev Drug Discov 2002; 1: 541-549.
14. Gulcher J, Stefansson K. An Icelandic saga on a centralized healthcare database and democratic decision making. Nat Biotechnol 1999; 17: 620.
15. Bell R. What can we learn from Herceptin trials in metastatic breast cancer? Oncology 2002; 63(Suppl 1): 39-46.
16. Masood S, Bui MM. Prognostic and predictive value of HER2/neu oncogene in breast cancer. Microsc Res Tech 2002; 59: 102-108.
17. Moskowitz DW. From pharmacogenomics to improved patient outcomes: angiotensin I-converting enzyme as an example. Diabetes Technol Therap 2002; 4: 519-532.
18. Basile VS, Masellis M, Potkin SG, Kennedy JL. Pharmacogenomics in schizophrenia: the quest for individualized therapy. Hum Mol Genet 2002; 11: 2517-2530.
19. Ingelman-Sundberg M. Polymorphism of cytochrome P450 and xenobiotic toxicity. Toxicology 2002; 181-182: 447-452.
20. Maggio ET, Shenderovich M, Kagan R, Goddette D, Ramnarayan K. Structural pharmacogenomics, drug resistance and the design of anti-infective super-drugs. Drug Discov Today 2002; 7: 1214-1220.
21. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA 2001; 286: 2270-2279.
22. Nebert DW, Jorge-Nebert L, Vesell ES. Pharmacogenomics 'individualized drug therapy' high expectations disappointing achievements. Am J Pharmacog 2003; 3: 361-370.
23. Kerwin RW. A perspective on progress in pharmacogenomics. Am J Pharmacog 2003; 3: 371-373.
24. Williams-Jones B, Corrigan OP. Rhetoric and hype where's the 'ethics' in pharmacogenomics? Am J Pharmacog 2003; 3: 375-383.
25. Cacabelos R. Pharmacogenomics for the treatment of dementia. Ann Med 2002; 34: 357-379.
26. Autere JM, Hiltunen MJ, Mannermaa AJ, Jakala PA, Hartikainen PH, Majamaa K et al. Molecular genetic analysis of the alpha-synuclein the parkin gene in Parkinson's disease in Finland. Eur J Neurol 2002; 9: 479-483.
27. Roses AD. SNPs - where's the beef? Pharmacog J 2002; 2: 277-283.
28. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW et al. Gene dose of apolipoprotein E type 4 allele the risk of Alzheimer's disease in late onset families [comment]. Science 1993; 261: 921-923.
29. Stefansson H, Sigurdsson E, Steinthorsdottir V, Bjornsdottir S, Sigmundsson T, Ghosh S et al. Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet 2002; 71: 877-892.
30. Stefansson H, Sarginson J, Kong A, Yates P, Steinthorsdottir V, Gudfinnsson E et al. Association of neuregulin 1 with schizophrenia confirmed in a Scottish population. Am J Hum Genet 2003; 72: 83-87.